Hot topics
A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA
In a review published in Pharmacology & Therapeutics,1 April issue, Professor Alberto Corsini, together with Professors John Chapman and Henry Ginsberg, Co-Chairs of PCSK9 Forum, make a critical appraisal of the efficacies, mechanisms of action, pharmacokinetics, pharmacodynamics and safety of the two classes of PCSK9…
read more »
Evolocumab prevents carotid artery wall thickening in paediatric HeFH
Treatment with evolocumab prevented carotid artery wall thickening in children with heterozygous familial hypercholesterolaemia (HeFH) who had not achieved LDL cholesterol (LDL-C) goals despite maximum tolerated background lipid-lowering therapies (LLTs). The study, published online in the European Journal of Preventive Cardiology,1 12 November, suggests using…
read more »
LDL binding to the LDL receptor: Structural insights
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Alan Remaley
read more »
AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Rick Vega
read more »
Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Dirk Blom
read more »
The trajectory of ASCVD: Focus on subclinical atherosclerosis
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Borja Ibanez
read more »
Post-ACS therapeutic strategies: What has changed?
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Matthew Budoff
read more »
CRISPR engineering of wild-type alleles versus millions of years of human evolution
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Steven Farber
read more »
The statin intolerant patient with ASCVD: What is your therapeutic strategy?
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Ioanna Gouni-Berthold
read more »
PCSK9 inhibition with a novel fusion protein
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Frederick Raal
read more »
Oral PCSK9 inhibition: Clinical update
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Christie Ballantyne
read more »
What do you do after a Statin? So many choices… what is yours?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Anne Goldberg
read more »
Keynote – HDL and PCSK9: Going for a ride?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Manuel Mayr
read more »
PCSK9 targeting: Inside versus outside?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Corsini
read more »
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon
read more »
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Erik Stroes
read more »
Aortic valve stenosis: A key pathophysiological role for Lp(a)?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Benoit Arsenault
read more »
Lp(a) and plaque progression: Insights from imaging
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Marc Dweck
read more »
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Stephen Nicholls
read more »
siRNA-mediated lowering of Lp(a) by Olpasiran
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Michael Koren
read more »
